Redeye initiates coverage of Klaria Pharma Holding AB, a Swedish biotech company, utilising its transmucoadhesive drug delivery technology platform to offer efficient and reliable treatments. We view the current share price as attractive for a significant long-term upside as we believe Klaria has the potential to provide next-generation drug delivery.

Read more and download the Research Report.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Redeye initiates coverage of Klaria Pharma Holding

© Modular Finance, source Nordic Press Releases